Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

09 November 2017 Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The Lancet Neurology publishes results from largest ever CIDP study.

> Read More
29 October 2017 Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting

Data on the preventive effects of HAEGARDA®, from a subgroup analysis from the Phase III COMPACT trial, presented at ACAAI 2017 Scientific Meeting.

> Read More
24 October 2017 New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

New data being presented at ACAAI Annual meeting highlighting preventive effect of HAEGARDA in HAE patients with a high frequency of attacks.

> Read More
12 October 2017 CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same

CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA) Hands-Only™ cardiopulmonary resuscitation (CPR) training to employees.

> Read More
28 September 2017 Japan’s Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment

Global biotherapeutics leader CSL Behring today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved AFSTYLA® (hereafter AFSTYLA) [lonoctocog alfa] a recombinant single-chain coagulation factor VIII (rVIII-SingleChain) in patients with haemophilia A (congenital factor VIII deficiency).

> Read More
Page 1 of 7 Next | Last

Share
LinkedIn Twitter Facebook Google+